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Key points 27 
25 articles were found. Most studies showed reduced LTBI or TB disease incidence after implementation of 28 
an intervention package, but evidence was weak for effectiveness of individual interventions. We make 29 
recommendations for future research to provide a better evidence base.  30 
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Abstract 32 
Evidence is limited for infection prevention and control (IPC) measures reducing Mycobacterium tuberculosis 33 
(MTB) transmission in health facilities. This systematic review, one of seven commissioned by the World 34 
Health Organization to inform the 2019 update of global tuberculosis (TB) IPC guidelines, asked: do triage 35 
and/or isolation and/or effective treatment of TB disease reduce MTB transmission in health care settings? 36 
Of 25 included articles, 19 reported latent TB infection (LTBI) incidence in health care workers (HCWs; 37 
absolute risk reductions 1%–21%); five reported TB disease incidence in HCWs (no/slight [high TB burden] or 38 
moderate [low burden] reduction) and two in HIV-positive in-patients (6%–29% reduction). 23/25 studies 39 
implemented multiple IPC measures; effects of individual measures could not be disaggregated. 40 
Packages of IPC measures appeared to reduce MTB transmission, but evidence for effectiveness of triage, 41 
isolation, or effective treatment, alone or in combination, was indirect and low quality. Harmonising study 42 
designs and reporting frameworks will permit formal data syntheses and facilitate policymaking. 43 
  44 
 
 Page 3 of 39 
Introduction 45 
Tuberculosis (TB) is the leading infectious cause of death worldwide.1,2 Health care workers (HCWs) are at 46 
higher risk of TB than the general population, likely because of exposure in health facilities.3–7 Infection 47 
prevention and control (IPC) measures to reduce Mycobacterium tuberculosis (MTB) transmission in health 48 
care settings are considered under three categories: environmental controls (e.g., mechanical ventilation); 49 
personal protection (e.g., using respirators); and administrative controls (e.g., coordinating efforts between 50 
governmental health departments).8 Evidence is limited, however, for the effectiveness of individual IPC 51 
measures in reducing MTB transmission, and guidelines have been written based heavily on expert opinion.9–52 
11 53 
This systematic review was one of seven complementary reviews commissioned by the World Health 54 
Organization (WHO) to inform the update of the 2009 TB IPC guidelines.12 It aimed to answer the question: 55 
do 1) triage of people with TB signs, symptoms or with confirmed TB disease; and/or 2) respiratory isolation 56 
of presumed or demonstrated infectious TB cases; and/or 3) effective treatment of TB disease reduce the 57 
transmission of MTB to HCWs or other populations (including patients and visitors) in health care settings, 58 
when compared with transmission to the same populations in settings without, or with different, IPC 59 
interventions? The primary findings of this review were presented to the WHO guideline development group 60 
(GDG) and collated in an online appendix to the 2019 guidelines.13 The guidelines contain recommendations 61 
for practice based on consideration of a wide range of evidence and should be the primary resource for 62 
implementation; this article looks more closely at how these interventions have been studied and discusses 63 
the implications for future TB IPC research. 64 
Methods 65 
The review protocol was registered on 12 February 2018 on the International Prospective Register of 66 
Systematic Reviews (ref. CRD42018085226).14 Countries were classified as high or low TB burden based on 67 
WHO lists published in 2016.15 68 
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Population, interventions, comparators, and outcomes 69 
Populations of interest were HCWs and non-HCWs working in/attending health care settings with applied 70 
intervention/s. Interventions of interest, specified by the WHO GDG, were: (1) triage based on signs, 71 
symptoms, or diagnosis of TB; (2) respiratory isolation (or spatial separation); and (3) effective treatment of 72 
TB based on bacteriologic susceptibility. WHO commissioned separate reviews to examine the use of 73 
environmental and personal protective measures.13 Comparators used were HCWs and non-HCWs working 74 
in/attending health care settings with no or different intervention/s. Outcomes of interest were differences 75 
in LTBI or TB disease incidence/prevalence or measures of relative difference in incidence/prevalence 76 
(Appendix 1). 77 
Search strategy, terms, and sources 78 
Search strategies were constructed and run by an experienced professional librarian (final search 30 79 
November 2017). Details of search terms and sources are provided in Supplementary tables 1 and 2. 80 
Selection of studies and inclusion and exclusion criteria 81 
Sifting (using criteria in Table 1) and data extraction were conducted in duplicate by two reviewers, with 82 
unresolved disagreements resolved by a third, independent reviewer, who also checked included articles. 83 
Citation tracking was conducted in Web of Science and/or Scopus® (details in Appendix 1). Systematic 84 
reviews meeting the inclusion criteria were used to find additional articles describing primary research and 85 
were not themselves included in the analysis. 86 
Data management and assessment of risk of bias 87 
Data management procedures are described in Appendix 1. Bias assessments were conducted at study level 88 
(using the Cochrane tool for experimental and prospective cohort studies [http://www.cochrane-89 
handbook.org] and Downs & Black for other observational studies)16 and at outcome level for Grading of 90 
Recommendations Assessment, Development and Evaluation (GRADE;17,18 using scales for before/after 91 
studies19 and cross-sectional studies [adapted Newcastle-Ottawa]). 92 
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Data analysis 93 
Due to the heterogeneity of the data, study designs, and populations studied, meta-analysis could not be 94 
conducted. Findings were synthesised using a narrative approach, with studies organised in line with key 95 
outcomes of interest pre-specified by WHO.14 96 
Results 97 
The search yielded 31,015 records; after removal of duplicates, 14,765 records were sifted by title and 98 
abstract (Figure 1). Forty-four articles were included: 25 primary research reports (Table 2) and 19 99 
systematic reviews (Supplementary table 3). Six TB IPC guidelines were also reviewed for possible primary 100 
research articles (Supplementary 3). Of the 25 studies, 17 (68%) were conducted in North America, three 101 
(12%) in sub-Saharan Africa, two (8%) in each of Europe and Latin America, and one (4%) in East Asia; 19 102 
(76%) were conducted in low TB burden (all high-income countries) and six (24%) in high TB burden settings 103 
(five upper middle- and one low-income country); and 24 (96%) were conducted in hospitals and one (4%) in 104 
primary care facilities. Only two (8%) studies reported outcomes in non-HCWs attending health care 105 
facilities; in both cases these were HIV-positive in-patients. Nineteen (76%) studies described LTBI incidence 106 
and seven (28%) described TB disease incidence (one described LTBI and TB disease incidence). 107 
Sixteen (64%) of 25 studies implemented interventions of interest in combination: 11 triage and isolation; 108 
two isolation and effective treatment; and three triage, isolation, and effective treatment (Figure 2, panel A). 109 
Of the remainder, eight (32%) studies assessed isolation alone and one (4%) assessed triage alone. An 110 
obstacle to the evaluation of the three IPC interventions of interest was the paucity of studies that 111 
introduced only these interventions: all studies, except two,21,22 implemented any or all of the three 112 
interventions as part of a wider suite of measures, including personal protective equipment (PPE) for HCWs; 113 
changes to ventilation and other environmental controls; and broader administrative controls (Table 3; 114 
Figure 2, panel B). Disaggregation of the effects of individual measures was not possible and it was therefore 115 
not feasible to attribute the entire reported effect on outcomes to a single intervention, or to estimate the 116 
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proportion of a demonstrated effect that could be attributed to the intervention (whether one, two, or all 117 
three elements of interest). 118 
Studies implementing triage of people with TB signs and/or symptoms 119 
Fifteen studies implemented triage: 11 (73%) in low burden settings, all in secondary or tertiary health 120 
facilities. Definitions of triage varied widely, from screening of patients “with pneumonia or evidence of 121 
TB”,35 to an “expanded respiratory isolation policy”.37,41 The only study to use triage alone used "routine 122 
chest x-ray screening for all new admissions".21 123 
Among 10 studies reporting changes in LTBI incidence (all implemented composite interventions), estimates 124 
of effect ranged from an absolute reduction of 2.3% (n = 21,197)41 to 20.5% (n = 65; Table 4).48 Of the four 125 
studies reporting incidence rates (IRs),28,32,37,38 IR ratios ranged from 0.18 to 0.9 (unadjusted; some 126 
calculated).  127 
Six studies reported changes in TB disease incidence; one that used only triage reported 78 episodes in 128 
38,331 PY before versus 12 episodes in 18,229 PY after implementation (calculated IR ratio 0.32).21 Two 129 
other studies in low burden settings also showed reduced risk/incidence after implementation of composite 130 
interventions.34,47 In contrast, three studies in high burden settings24,28,29 showed small or no reductions in 131 
risk/incidence after use of triage (and other interventions), from 3.7% to 3.2%,29 0.65 to 0.44 per 100 PY,28 132 
and an adjusted odds ratio (OR) of 0.97 (95% CI 0.90–1.04)24 comparing hospitals with higher versus lower 133 
administrative scores (Table 4). 134 
Studies implementing isolation or spatial separation 135 
Twenty-four studies22,24–29,31–38,40–43,45–49 implemented respiratory isolation or spatial separation; 18/24 (75%) 136 
were in low burden countries. All studies, except one,22 used isolation together with other TB IPC measures. 137 
Among the 19 studies22,26–28,31–33,35–38,40–43,45,46,48,49 reporting differences in LTBI incidence, effects ranged from 138 
a 1% increase (n = 4,060)33 to a 20.5% reduction (n = 65; Table 4).48 The two largest studies (one each in the 139 
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USA and Brazil) showed absolute reductions in LTBI incidence (1.2%42 and 1.7%).27 Among six studies 140 
reporting IRs, IR ratios (intervention versus no intervention) ranged from 0.01 (95% CI 0–0.04; p <0.001; 141 
adjusted, covariates unclear)28 to 0.24 (95% CI 0.10–0.54; adjusted for exposure and occupation)26 and 0.46 142 
(calculated from data).38 Among the six studies that reported changes in TB disease, estimates of effect 143 
differed by setting, from almost no difference in incidence in the four studies in high burden settings,24,25,28,29 144 
to absolute reductions of 6% (n = 409)47 and 29% (n = 134; calculated)34 in low burden settings. 145 
Studies implementing effective treatment based on drug susceptibility 146 
Five studies31,45–48 used effective treatment with other IPC measures. ‘Effective treatment’ was defined 147 
variably, from a change in regimen from three to four drugs,48 to the use of “radiometric susceptibility 148 
testing,”31 which, it was assumed, would have led to appropriate treatment, though this is not stated.  149 
Two studies did not report outcomes for all participants/sites.31,45 All studies showed absolute reductions in 150 
TST conversion after implementation of IPC measures, ranging from 2.1%46 to 20.5%48 (crude; calculated), 151 
though all studies had small numbers of outcomes (range 10–104) and two had small sample sizes (n ≤650). 152 
Only one study47 used effective treatment and measured TB disease incidence, employing an “expanded 153 
anti-TB regimen” (a change from median 1.5 [range 0–4] to 2.0 [range 0–4] drugs) as part of a composite 154 
intervention that included triage, isolation, and changes to diagnostic processes. They found a change in TB 155 
disease risk (or “attack rate”) among HIV-positive individuals admitted to the ward, from 8.8% before, to 156 
2.6% after intervention (p = 0.01). 157 
Quality assessment and GRADE 158 
All 18 retrospective studies scored poorly (median 10/27 [IQR 8.3–12.0; range 6–13]; Table 5). The seven 159 
prospective studies also scored poorly (Table 6): one study was marked down for incomplete outcome 160 
reporting and three for selective outcome reporting. The overall low study quality was reflected in the 161 
GRADE assessment (Appendix 3; Supplementary tables 4–9), where the strength of evidence was 162 
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consistently downgraded due to serious risk of bias and very serious indirectness (the latter often due to the 163 
concurrent use of multiple IPC measures). 164 
Discussion 165 
This review found 25 studies, published from 1957–2017, that reported the effects of triage, isolation, and 166 
effective treatment on the incidence of LTBI or TB disease in HCWs and others attending health facilities. 167 
Most studies were conducted in the 1990s in USA hospitals, several in response to outbreaks of TB.22,34,45–48 168 
Almost all studies showed reduced LTBI or TB disease incidence after implementation of a package of IPC 169 
measures, but, because of heterogeneity in study design and reporting of results, meta-analysis was not 170 
conducted. Studies were generally of low quality. All studies, except two, tested composite interventions, 171 
including other administrative measures, PPE, and environmental measures; it was therefore not possible to 172 
disaggregate the effects of specific interventions from those of the others described. 173 
It is important that these findings should not be interpreted to suggest a lack of efficacy of the TB IPC 174 
measures examined; effective treatment, in particular, is supported by studies outside health care settings50 175 
and studies from health care settings using guinea pigs as infection endpoints.13 Indeed the WHO 2019 TB 176 
IPC guidelines recommend all three examined measures as first-line controls to be used as part of broad 177 
suite of interventions.12 Statements, in the guidelines, around “low certainty” and “indirectness” reflect the 178 
overall poor study quality, heterogeneity in study design, implementation of multiple interventions at one 179 
time, predominance of studies from a particular type of setting, and deficiencies in the reporting of results. 180 
These issues are discussed below.  181 
Gaps in the literature  182 
Most studies were from high-income, low TB burden settings, predominantly the USA. Conspicuously absent 183 
were countries with very high TB burdens, such as India and China, and countries in sub-Saharan Africa and 184 
South or Central America (other than South Africa, Malawi, and Brazil), where the LTBI burden among HCWs 185 
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is known to be very high.3,4 Data from these countries are essential if global policy is to address successfully 186 
the broad range of environments in which IPC measures must be implemented. 187 
Only one study was conducted in a primary care setting.25 Though many people with TB in low burden 188 
countries may receive treatment in hospitals, most in high burden countries are cared for as out-patients 189 
and may not visit a hospital at any point in their illness.51 WHO widely recommends the decentralisation of 190 
TB care,52,53 though for DR-TB this policy is variably effected.2 As shown in South Africa,54–57 HCWs in clinics 191 
and the community are also at high risk of TB infection and disease. Evidence is still needed for the 192 
effectiveness of IPC measures in these environments, which present different challenges for implementing 193 
interventions and measuring outcomes.58,59 194 
Many studies provided detailed descriptions of interventions used but often did not describe, in any depth, 195 
fidelity to these interventions. Cross-sectional studies24,25,40,42 were the weakest in this regard, as they were 196 
able only to assess whether an intervention or policy had been instated, and not if it was being applied as 197 
intended. (Additional methodological shortcomings in some cross-sectional studies further reduced 198 
confidence in their findings; for example, the study by Claassens et al.,25 where IPC coverage was estimated 199 
after the period during which outcomes were enumerated.) Some reporting of fidelity is essential to 200 
strengthen what is already very indirect evidence for the effectiveness of these interventions.  201 
A consistent finding was the lack of reporting of secular changes in TB incidence or prevalence among people 202 
attending the facility over the course of the study. This is particularly relevant given the high number of 203 
before-after or during-after studies included, where the same facility/ies at different time points served as 204 
control and intervention. Changes in the numbers of potentially infectious individuals attending study 205 
facility/ies may have had a dramatic effect on the risk of MTB transmission to HCWs, and reductions in LTBI 206 
or active TB incidence may have been misattributed to the implementation of IPC measures. Measurement 207 
of secular changes is recommended by guidance on conducting before-after studies19 and should be a 208 
standard reporting requirement for future studies. 209 
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Incidence of LTBI or TB disease in HCWs are useful ways to estimate MTB transmission from patients in 210 
health care settings. Transmission between patients and from HCWs to patients does, of course, occur, 211 
though this was measured by only two studies, both in low TB burden, high-income countries.34,47 Choice of 212 
at-risk population, outcomes, and outcome measurement are critical when studying MTB transmission, but 213 
can also make study design more complex.60 In high TB burden countries, a high proportion of HCWs already 214 
have LTBI, limiting the size of the at-risk population. Using TST to measure LTBI incidence (as in several of the 215 
included studies) can also be problematic, as reactions can vary based on host factors. The development of 216 
TB disease, though easier to measure, is also dependent on a number of interconnected host factors and, in 217 
the absence of complementary molecular epidemiological data, is more difficult to reliably attribute to a 218 
congregate setting transmission event. More detailed descriptions of at-risk HCW populations would allow 219 
for better extrapolation of findings to other key populations, particularly HIV-positive individuals, and 220 
provide better guidance on how to prevent TB in HCWs. As discussed by Harries et al.,29 robust occupational 221 
health programmes are critical to the well-being of frontline HCWs; embedding TB IPC studies within existing 222 
occupational health frameworks may allow for better reporting of individual HCW risk profiles and improve 223 
long-term fidelity to interventions. 224 
Future research 225 
This review, like others,4,6,7,11,61 found limited and low quality evidence for the effectiveness of administrative 226 
IPC measures in reducing MTB transmission, with over-representation of data from hospitals in high-income, 227 
low TB burden countries. Like previous reviewers, we call for better designed and implemented studies from 228 
a wider variety of settings, though we acknowledge the difficulties of doing this in what are often 229 
unpredictable environments and recognise the shortcomings in the methods available to measure MTB 230 
transmission in these settings.62,63  231 
Despite the weaknesses in the data presented here, the weight of evidence to support the use of established 232 
TB IPC measures is sufficient that it would be unethical to conduct randomised trials involving a true ‘control’ 233 
arm, though trials comparing ‘best practice‘ IPC interventions with an established basic standard of care 234 
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should still be considered, as should the use of pragmatic trial designs, such as stepped wedge cluster 235 
randomised trials.64 We would suggest a change in expectations and an acceptance of the limitations 236 
inherent in conducting these complex interventional studies in challenging clinical settings. Standardisation 237 
of study designs, outcome measurement, and reporting formats, with replication of clusters or sites would 238 
facilitate the generation of more robust data syntheses to guide policymaking, as would efforts by 239 
investigators to provide more precise and comprehensive data in the areas discussed above. We suggest 240 
that greater numbers of imperfect but comparable data from studies conducted in a wide range of settings 241 
that adhere to a set of standardised rules around design and reporting would be more useful to decision-242 
making than a few perfectly-designed studies conducted in places unrepresentative of those where effective 243 
interventions are most needed. Additionally, quasi-experimental techniques, such as interrupted time-series 244 
analysis,65–67 with or without controls,68 or difference of differences approaches have been employed with 245 
success in evaluating complex public health policy interventions in rapidly changing environments69 and 246 
should be considered seriously for future real-world estimations of the effectiveness of TB IPC measures. To 247 
this end, given the difficulties outlined above around measurement of outcomes, confounding, bundling of 248 
interventions, and valid comparator groups, it would be beneficial to have additional specific guidance, 249 
developed by relevant experts, to help investigators plan, conduct, and report studies examining the efficacy 250 
of measures to reduce MTB transmission. 251 
Limitations and strengths 252 
‘Prompt initiation of effective treatment’ is widely considered a reliable way to reduce MTB transmission 253 
and is the wording used in the WHO 2019 TB IPC guidelines.12 The five studies included in this review that 254 
used effective treatment did not report time to treatment and, because ‘prompt initiation of effective 255 
treatment’ was not one of the defined interventions of interest, studies examining its efficacy in reducing 256 
transmission were not included for analysis. 257 
Heterogeneity of the data and weaknesses in study design prevented meaningful quantitative synthesis, 258 
which may have provided a clearer guide for policymakers. Studies may have been overlooked during sifting 259 
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or published in non-specified languages. Strengths include the application of a robust search strategy by a 260 
professional librarian across a wide range of repositories, all sifting and data extraction being done in 261 
duplicate (per PRISMA recommendations; Appendix 4),70 and the use of GRADE to assess quality.  262 
Conclusions 263 
This review found 25 studies implementing triage, isolation, or effective treatment and measuring the 264 
incidence of LTBI or TB disease or both. Overall, packages of IPC measures appeared to reduce MTB 265 
transmission, but studies were of low quality and evidence for the effectiveness of individual or combined 266 
measures was indirect and of limited utility; heterogeneity of the data prevented meta-analysis. More data 267 
are needed from high-burden, lower-income, primary care settings. Harmonisation of study designs and 268 
reporting frameworks will allow for more formal data syntheses, creating a better platform for policymaking. 269 
The development of specific guidance around conducting and reporting studies to determine the efficacy of 270 
TB IPC measures should be prioritised by governing and stakeholder bodies. 271 
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Tables and figures 461 
Table 1. Inclusion and exclusion criteria used during sifting process 462 
Inclusion criteria Exclusion criteria 
Types of 
participants 
Studies of:  
1) HCWs (including CHWs) working in health care 
settings; or 
1. Any study not in humans 
2. Any study that did not report any of 
the above-stated outcomes of interest 
3. Any study reporting solely on primary 
outcomes of interest without a control 
or comparator group. 
4. Any systematic review superseded by 
an updated systematic review 
5. Narrative reviews not adding new data 
or new analysis of data to existing 
knowledge 
6. Commentaries and mathematical 
modelling studies 
7. Studies with fewer than 10 participants 
per comparator arm 
8. Any study not written in English, 
Japanese, Chinese, Russian, French, 
Spanish or Portuguese 
9. Any study published before 1946 
2) Other staff working in a health care setting; or  
3) Persons of all ages (patients and visitors) attending 
health care settings, anywhere in the world. 
Types of 
intervention 
At least one of:  
1) Triage of people with TB signs or TB symptoms or 
confirmed TB; 
2) Respiratory isolation (spatial separation) of 
presumed infectious TB cases; or  
3) Effective treatment of TB based on bacteriologic 
susceptibility 
Types of 
comparator 
Studies reporting data (for outcomes of interest) from a 
control or comparator group of HCWs (including CHWs) 
working in health care settings, or other staff or persons 
of all ages (patients and visitors) attending health care 
settings, with no or different administrative infection 
control interventions. 
Types of 
outcome 
measures 
Studies reporting data on at least one of the outcome 
measures of interest (incidence/prevalence of LTBI or 
TB disease). 
Types of 
study 
Any consecutive case series, case control study, cohort 
study, randomised controlled study, systematic review, 
or meta-analysis. 
CHW: community health workers; HCWs: health care workers; LTBI: latent tuberculosis infection; TB: tuberculosis 463 
  464 
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Table 2. Summary of characteristics of primary research studies included (n = 25) 465 
Characteristic Number of studies conducted 
Overall, n (%/25) In low burden* 
countries, n (row %) 
In high burden* 
countries, n (row%) 
All 25 (100) 19 (76.0)† 6 (24.0)‡ 
Period conducted§    
 Pre-1990 2 (8.0) 2 (100) 0 
 1990–1999 17 (68.0) 15(88.2) 2 (11.8) 
 2000–2009 5 (20.0) 2 (40.0) 3 (60.0) 
 2010 and later 1 (4.0) 0 1 (100) 
Study design    
 Cross-sectional 5 (20.0) 2 (40.0) 3 (60.0) 
 Before/after 12 (48.0) 10 (83.3) 2 (16.7) 
 During/after 8 (32.0) 7 (87.5) 1 (12.5) 
Level of facility    
 Primary 1 (4.0) 0 1 (100) 
 Secondary/tertiary 24 (96.0) 19 (79.2) 5 (20.8) 
Group/s studied    
 HCWs 23 (92.0)  17 (73.9) 6 (26.1) 
 Other individuals 2 (8.0) 2 (100) 0 
Interventions implemented¶    
 Triage 15 (60.0) 11 (73.3) 4 (26.7) 
 Isolation 24 (96.0) 18 (75.0) 6 (25.0) 
 Effective treatment 5 (20.0) 5 (100) 0 
Outcomes measuredǁ    
 LTBI incidence** 19 (76.0) 16 (84.2) 3 (15.8) 
 TB disease incidence** 7 (28.0) 3 (42.9) 4 (57.1) 
*Based on WHO 2016 definitions15 466 
†Of the 19 studies in low burden countries, 17 (89%) were conducted in North America and two (11%) in Europe; all 19 467 
were conducted in high-income countries (per World Bank classifications at the time of study).20 468 
‡Of the six studies in high burden countries, three (50%) were conducted in sub-Saharan Africa, two (33%) in Latin 469 
America, and one (17%) in East Asia; five (83%) were conducted in upper-middle income countries and one (17%) in a 470 
low-income country (per World Bank classifications at the time of study).20 471 
§Based on last year of data collection 472 
¶Interventions of interest only; several studies implemented more than one intervention of interest 473 
ǁOne study estimated incidence of both LTBI and TB disease 474 
**Generally reported as a risk or incidence rate 475 
HCWs: health care workers; LTBI: latent tuberculosis infection; TB: tuberculosis 476 
 477 
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Table 3. Setting, design, population(s) studied, intervention(s) implemented, and outcome(s) measured in the studies included, divided by high/low TB burden* 478 
countries and listed in reverse chronological order of publication (n = 25) 479 
First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
HIGH BURDEN*        
O’Hara, 201724 28 public 
hospitals, 
South Africa 
Cross-
sectional 
HCWS: all 
individuals 
working at study 
hospitals 
TB infection control audit in 
2012; separate score for 
administrative controls (triage, 
isolation) 
Scores also for (i) 
environmental controls; (ii) 
personal respiratory 
protection; and (iii) 
miscellaneous measures, as 
well as overall score 
Facilities with 
higher vs. those 
with lower 
administrative 
scores (a higher 
score equalled 
more IPC measures 
in place). 
TB disease incidence  
(Episodes of TB disease per 
100,000 HCWs | Ascertained 
through review and probabilistic 
matching of HR and TB register) 
Claassens, 
201325 
121 primary 
health care 
facilities, 
South Africa 
Cross-
sectional 
HCWs: all 
individuals 
employed at 
study facilities 
TB infection control audit in 
May–Sep 2009; separate score 
for administrative controls 
Scores also for (i) 
environmental controls and 
(ii) personal respiratory 
protection, as well as overall 
score 
Facilities with 
higher vs. those 
with lower 
administrative 
scores (a higher 
score equalled 
more IPC measures 
in place). 
TB disease incidence, Jan 2006–
Dec 2008 
(Binary outcome defined as ≥1 
TB episode among HCWs in a 
facility vs. 0 episodes | 
Ascertained through 
questionnaire answered by 
facility manager) 
da Costa, 200926 One hospital, 
Brazil 
During/ 
after  
HCWs: admin 
clerks, 
housekeepers, 
lab/radiology 
techs, nurses, 
physicians, 
social workers  
Isolation of: all patients with 
sputum sent for AFB +/- 
mycobacterial culture, patients 
with productive cough until one 
smear negative, and HIV+ 
patients with abnormal CXR; and 
Education of HCWs 
Specialised TB o/p clinic. Use 
of N95 respirator for all 
person entering room with 
isolated patient. Patients 
leaving room for diagnostic 
tests wore surgical mask and 
educated on cough etiquette. 
Period after (2002–
2003) vs. period 
during (1998–2001) 
implementation of 
IPC measures.† 
LTBI incidence   
(TST conversions per 1000 PM | 
Annual serial TST, positive 
defined as ≥10 mm induration, 
conversion as ≥10 mm 
induration if initial two-step or 
≥15 mm if initial one-step )  
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Roth, 200527 Four general 
hospitals, 
Brazil 
Cross-
sectional 
HCWs: 
administrative 
workers, 
auxiliary staff, 
nurses, and 
physicians  
Rapid diagnosis, treatment, and 
isolation. 
Some hospitals had 
engineering measures 
(negative pressure isolation 
rooms with HEPA filtration 
and 20 ACH; N95 respirator 
for HCWs and surgical mask 
for patient until isolated.  
Compared all four 
hospitals and two 
hospitals (A & B) 
with better IPC vs. 
two hospitals (C & 
D) with worse IPC 
measures. 
LTBI prevalence and LTBI 
incidence  
(Prevalence of positive TST and 
TST conversions per 1000 PM | 
Induration ≥10 mm, if <10 mm, 
TST repeated after 7–10 days) 
Yanai, 200328 One referral 
hospital, 
Thailand 
Before/ 
after 
HCWs: no 
further details 
provided 
Interventions (SOPs & IPC plan) 
aimed at: time from admission 
to initiation of TB treatment; 
timeliness of suspicion of TB; 
collection of specimens; 
reporting results, isolation, & 
initiation of treatment 
monitored 
Prevention interventions for 
HCWs & patients; 
engineering control measures 
(negative & natural 
ventilation; in lab, air exhaust 
and UVGI) and personal 
respirators (N95 masks 
encouraged when HCWs 
exposed to infectious TB 
patients. Lab staff processing 
MTB cultures used personal 
respirators). 
Period after (1998–
1999) vs. period 
before (1995–1997) 
implementation of 
IPC measures. 
LTBI incidence rate and TB 
disease incidence  
(TST conversions per 1,000 PY 
and TB disease incidence per 100 
PY | Annual two-step TST 
screening, positive defined as 
induration ≥10 mm; CXR, sputum 
smear and culture for all HCWs 
with symptoms or signs of active 
TB, those on treatment entered 
into HCW-specific register) 
Harries, 200229 40 hospitals, 
Malawi 
Before/ 
after 
HCWs: all 
hospital-based 
staff with 
frequent 
exposure to 
medical patients 
Guidelines on TB IPC (mid-1998), 
including prioritising those with 
cough; rapid collection of 
sputum; frequency of processing 
specimens; & spatial separation 
of people with possible PTB 
Ventilation (windows left 
open) and masks (worn by TB 
patients when undergoing 
surgery) 
Period after (1999) 
vs. period before 
(1996) 
implementation of 
IPC measures. 
TB disease incidence  
(Number/proportion of HCWs 
registered with TB | Consultation 
of administrative records and 
interviews with TB officers; 
details published separately 30) 
LOW BURDEN*        
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Welbel, 200931 One public 
hospital, USA 
During/ 
after 
HCWs: non-
clinical and 
clinical staff, 
including 
physicians, 
nurses, and 
training medical 
staff 
Creation of respiratory isolation 
service for proper & prompt 
isolation of patients; dedicated 
technician for service, collection 
of sputum daily. All HIV+ patients 
with respiratory symptoms 
placed in isolation. Implemented 
1992–1997. 
Engineering changes 
(negative pressure, UV 
lights); N95 respirators 
introduced in 1997. 
Period after (1998–
2002) vs. period 
during (1994–1997) 
implementation of 
IPC measures. 
LTBI incidence  
(TST conversions per 100 PY | 
Institutional 2-step TST 
programme established per CDC 
recommendations; positive 
defined as induration ≥10 mm) 
Baussano, 
200732 
Three health 
units, Italy 
Before/ 
after 
HCWs: clerical, 
nursing, 
medical, & SW 
with negative 
TST and no 
previous 
vaccination with 
BCG 
Implementation of regional 
guidelines. Administrative: 
appointment of TB official at 
each facility; adoption of 
procedures to assess risk of TB 
transmission; prompt diagnosis 
& isolation of potentially 
infectious TB cases 
Organisational, technical & 
educational interventions; 
respiratory protection 
measures, particularly while 
performing cough-inducing 
procedures. 
Period after (2002–
2004) vs. period 
before (1998–2000) 
implementation of 
IPC measures. 
LTBI incidence  
(TST conversions per 100 PY, sex 
& age-adjusted | Positive 
defined as induration of ≥10 mm 
after previous negative TST)  
Jones, 200233 One teaching 
medical 
centre, USA 
During/ 
after 
HCWs: 
employees of 
the medical 
centre (no other 
details 
provided) 
Rule-out negative pathway: (1) 
initiation of respiratory isolation 
protocols; (2) direct patient 
admission/transfer to Special 
Immunology/Infectious Disease 
[SI/ID] unit; and (3) immediate 
patient placement in respiratory 
isolation 
Isolation rooms designed to 
provide negative pressure, six 
air exchanges/hour, and 
venting of air outside. 
Period after (Jan-
Jun 1998) vs. period 
during (1994–1998) 
the implementation 
of the pathway. 
LTBI incidence 
(TST conversions | Review of 
employee health records) 
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Moro, 200034 One HIV ward 
in one 
hospital, Italy 
Before/ 
after 
HIV+ individuals 
admitted to 
outbreak ward 
whose stay 
overlapped with 
infectious 
periods of MDR-
TB patients 
Strict AFB isolation procedures 
initiated for all patients with 
respiratory disease or fever. 
Patients wore surgical masks 
when being transported for 
diagnostic purposes. Surgical 
masks mandatory for persons 
entering pts rooms. 
Period after (Jul 
1993–Feb 1994) vs. 
before (Oct–Jun 
1993) the 
implementation of 
IPC measures. 
MDR-TB disease incidence  
(New cases per 1,000 PD | Case 
definition: signs, symptoms, and 
an isolate resistant to at least 
one first-line drug; medical and 
microbiology records consulted 
to ascertain history & drug 
susceptibility) 
Bangsberg, 
199935 
One tertiary 
referral 
centre, USA 
During/ 
after 
HCWs: medical 
house staff 
All patients known HIV+, with 
HIV risk factors, or homelessness 
presenting with 
pneumonia/evidence of TB 
isolated on presentation at ED; 
admitted to negative-pressure 
isolation room; and remained in 
respiratory isolation until three 
negative AFBs. 
Implementation of revised 
policy in 1992 based on CDC 
guidelines (published in 
1993). 
Modifications to facility & 
personal protective 
equipment. 
Period after (Dec 
1992–Jun 1994) vs. 
during (Jun 1992) 
the implementation 
of IPC measures. 
LTBI incidence  
(TST conversions per 100 PY | 
Positive defined as induration of 
≥10 mm, conversion as increase 
of ≥6 mm to a value of at least 
10 mm) 
Behrman, 
199836 
ED in one 
hospital, USA 
Before/ 
after 
HCWs: all 
employees at 
study hospital 
New TB control measures in the 
ED, including four respiratory 
isolation rooms. 
100% non-recirculated air in 
trauma area, improved 
ventilation, laminar flow of 
air from registrars to 
patients, and acrylic plastic 
droplet shields for registrars. 
Period after (1996) 
vs. period before 
(Jul 1994–Dec 1995) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions | Positive 
defined as induration of ≥5 mm 
after 48–72 hours) 
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Blumberg, 
199837 
One public 
hospital, USA 
During/ 
after 
HCWs: staff in a 
teaching 
program (50% of 
their clinical 
rotations in the 
hospital) 
Mandatory isolation of all 
patients with active TB, those 
with TB from differential 
diagnosis (or when sputum tests 
ordered), HIV+ or at high risk of 
HIV infection. Isolation 
discontinued after 3 consecutive 
negative AFBs/patient 
discharged. 
Interim engineering controls 
(conversion of 90 rooms to 
negative pressure rooms by 
addition of window fan); 
personal respiratory 
protection equipment 
(submicron mask used by all 
HCWs entering respiratory 
isolation room. 
Period after (Jan 
1993–Jun 1997) vs. 
period during (Jul–
Dec 1992) 
implementation of 
IPC measures. 
LTBI incidence  
(TST conversions per 100 PY | 
One-step testing; positive 
defined as induration of ≥10 mm 
after 48–72 hours) 
Louther, 199738 Urban hospital 
with a 
dedicated 
‘AIDS centre’, 
USA 
During/ 
after 
HCWs: All 
employees at 
study hospital 
(excluding those 
with boosted 
response to 
serial TST) 
Respiratory isolation of all 
individuals suspected of having 
active TB;  
Triage of people attending 
ED/OPD and isolation of HIV+ 
people with particular symptoms 
(details published separately 39)  
Negative-pressure ventilation 
rooms 
Germicidal UV (n = 125 units) 
in patient rooms, waiting 
areas, and nursing stations 
PPE: Technol shield masks, 
dust-mist-fume respirators, 
and HEPA respirators 
Period after (1993–
1994) vs. period 
during (1991–1992) 
implementation of 
IPC measures. 
LTBI incidence 
(Percentage TST conversions | 
Positive defined as induration 
≥10 mm within 2 years of a 
previous negative result) 
Uyamadu, 
199722 
One teaching 
hospital, USA 
Before/ 
after 
HCWs: all staff 
at study hospital 
Mandatory respiratory isolation 
of all patients with community-
acquired pneumonia, until two 
negative AFBs/TB ruled out on 
clinical grounds 
None Period after (1988–
Jul 1991) vs. period 
before (Jul 1991–
1994) 
implementation of 
isolation 
LTBI incidence 
(Percentage TST conversion | 
Positive defined as induration 
≥10 mm after 48–72 hours) 
Sinkowitz, 
199640 
1,494 
hospitals, USA 
Cross-
sectional 
Bronchoscopists 
and other HCWs 
 
Compliance with 1990 CDC TB 
guideline AFB isolation room 
(survey conducted in March 
1993, 50% response rate). 
All 4 criteria; at least 3 
criteria (negative-pressure, 
exhaust directed outside & 
single/cohorting of patients); 
at least negative-pressure 
criterion; at least the direct 
outside exhausted air 
criterion 
Hospitals 
implementing all 
four CDC criteria vs. 
those not 
implementing all 
four criteria 
LTBI incidence 
(TST conversions measured in 
1992, stratified by number of TB 
patients hospitalised in 1992 | 
Hospitals reported on proportion 
of HCWs with TST ≥10 mm and 
previous negative result) 
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Blumberg, 
199541 
One public 
hospital, USA 
During/ 
after 
HCWs at the 
hospital (not 
those on 
rotation) 
Mandatory isolation of all 
patients with active TB, those 
with TB from differential 
diagnosis (or when sputum tests 
ordered), HIV+ or at high risk of 
HIV infection. Isolation 
discontinued after 3 consecutive 
negative AFBs/patient 
discharged. 
Interim engineering controls 
and personal respiratory 
protection equipment (per 
Blumberg, 1998, above). 
Period after (Jul 
1992–Jun 1994) vs. 
period during (Jan–
Jun 1992) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions | One-step 
testing; positive defined as 
induration ≥10 mm after 48–72 
hours) 
Fridkin, 199542 210 hospitals, 
USA 
Cross-
sectional 
HCWs, 
measured in 
1992, among 
hospitals 
reporting at 
least 6 TB 
patients in 1992 
Compliance with 1990 CDC TB 
guideline AFB isolation room 
(survey conducted in March 
1993, 50% response rate). 
1. All 4 criteria no vs. yes 
(includes single/cohorting of 
patients);  
2. ≥ 3 criteria (includes 
single/cohorting of patients). 
Per Sinkowitz, 1996, above. Hospitals 
implementing all 
four CDC criteria vs. 
those not and 
hospitals 
implementing ≥3 
CDC criteria vs. 
those not  
LTBI incidence 
(TST conversions | Reported 
percentage of HCWs who 
received a TST that became 
newly positive) 
Holzman, 
199543‡ 
One municipal 
hospital, USA 
Before/ 
after 
Non-physician 
HCWs: nursing, 
housekeeping, 
radiology, and 
other staff  
Implementation of 1990 CDC 
guidelines. Triage; early isolation 
& treatment (drug-susceptibility 
testing not specified); written 
criteria for starting/stopping 
precautions. 
Negative pressure rooms 
with ventilation, filtration, 
and UV radiation equivalent 
to 28 air changes/hour; PPE: 
dust-mist & HEPA respirators. 
Period after (Nov 
1993–Oct 1994) vs. 
period before (Nov 
1992–Oct 1993) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions | Not 
described, cite CDC 1994 
guidelines 44) 
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Jarvis, 199545 Three 
hospitals 
(A[1989–91], B 
[1989–91] & D 
[1990–1]), 
USA 
Before/ 
after 
HCWs with 
baseline 
negative TST 
result and 
follow-up TST 
within 2 years 
Implementation of 1990 CDC 
guidelines, including education 
of HCWs to increase index of 
suspicion for TB; prompt 
collection & processing of 
specimens; and prompt 
identification & isolation of pts 
with known/suspected TB. 
Engineering controls 
(negative pressure isolation 
rooms & air exhausted 
outside) and respiratory 
protective devices 
(submicron or dust-mist).  
Period after (not 
defined) vs. period 
before (not 
defined) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions | Positive 
defined as induration ≥10 mm if 
unknown baseline or ≥10 mm 
increase on baseline induration) 
Maloney, 
199546 
One teaching 
hospital, USA 
Before/ 
after 
HCWs with 
documented 
negative TST in 
previous 24 
months 
Implementation of 1990 CDC 
guidelines, including prompt 
isolation & treatment of patients 
with TB; rapid diagnosis. 
Negative-pressure isolation 
rooms; moulded surgical 
masks for HCWs. 
Period after (Jul 
1991–Aug 1992) vs. 
period before (Jan 
1990–Jun 1991) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions| Positive 
defined as induration ≥10 mm) 
Stroud, 199547 One hospital, 
USA 
Before/ 
after 
“AIDS patients” 
with same ward 
exposure to 
MDR-TB pts 
Aggressive implementation of 
administrative controls: rapid 
placement of TB patients or 
suspected TB patients in single-
patient rooms. Expanded TB 
treatment prescribed.  
In period III, engineering 
changes (some isolation 
rooms fitted with UV lights 
and fans that exhausted air 
outside) provided ≥6 air 
exchanges/hour and created 
negative pressure in hallway. 
Period after (Apr 
1990–May 1991) vs. 
period before (Jan 
1989–Mar 1990) 
implementation of 
IPC measures. 
MDR-TB disease risk 
(“Attack rate”, expressed as % | 
Case definition: diagnosis of 
active TB during study period 
with MTB isolate resistant to at 
least isoniazid and streptomycin, 
ascertained through review of 
hospital and medical records) 
Wenger, 199548 One HIV ward 
in hospital, 
USA 
Before/ 
after 
HCWs working 
on the HIV ward 
Higher index of suspicion for TB, 
stricter criteria for discontinuing 
isolation; restriction of cough 
procedures to isolation rooms; 
expansion of initial TB treatment 
to 4 agents; shorter turnaround 
time for AFB, DST. 
Negative pressure, masks Period after (Jun 
1990–Jun 1992) vs. 
period before (Jan–
May 1990) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversions | Positive 
defined as induration ≥10 mm 
and ≥6mm larger than previously 
reported induration) 
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First author, 
year published 
Setting Study 
design 
Population/s Intervention/s Comparator Outcome  
(Metric reported | How 
measured) Administrative Other 
Bryan, 198349 One teaching 
hospital, USA 
During/ 
after 
HCWs (no 
details 
provided)  
TB Registry: documents 
dates/results of AFBs, CXR 
results, and whether patient is 
put in respiratory isolation & 
when; register reviewed weekly 
by TB epidemiologist 
None Period after (1977–
1981) vs. period 
during (1976) 
implementation of 
IPC measures. 
LTBI incidence 
(TST conversion rates | One-step 
testing; no other details 
provided) 
Jacobson, 
195721 
One general 
hospital, USA 
Before/ 
after 
HCWs: hospital 
employees 
(before 1952, 
only physicians, 
student nurses 
and TB staff 
examined 
regularly) 
Routine CXR screening 
programme for new admissions 
None Period after (1952–
1955) vs. period 
before (1942–1951) 
implementation of 
screening 
programme. 
TB disease incidence rate 
(TB cases per 1,000 PY | ) 
*Based on WHO 2016 definitions15 480 
†This paper refers to both 1998–2001 and 1999–2001 as the first period of observation; 1998–2001 used for the purposes of this review. 481 
‡Conference abstract only 482 
↑: increase; ↓: decrease; ACH: air changes per hour; adj.: adjusted; admin: administrative; AFB: acid-fast bacilli; AIDS: acquired immune deficiency syndrome; BCG: bacille 483 
Calmette-Guérin; CDC: Centers for Disease Control and Prevention; CI: confidence interval; CXR: chest x-ray; DST: drug sensitivity testing; ED: emergency department; HCWs: health 484 
care workers; HEPA: high efficiency particulate air; HIV+: HIV-positive; HR: human resources; IPC: infection prevention and control; lab: laboratory; MDR: multidrug-resistant; MTB: 485 
Mycobacterium tuberculosis; mth: month; o/p: outpatient; OR: odds ratio; PD: person-day; PM: person-month; pt: patient; PY: person-years; SOP: standard operating procedure; 486 
SW: social worker; TB: tuberculosis; tech: technician; TST: tuberculin skin test; unadj.: unadjusted; USA: United States of America; UV: ultraviolet; UVGI: ultraviolet germicidal 487 
irradiation 488 
  489 
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Table 4. Main findings of included studies divided by high/low TB burden* countries and listed in reverse chronological order of publication (n = 25) 490 
First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
HIGH BURDEN           
O’Hara, 201724 South 
Africa 
Yes Yes No Yes TB disease | 
HCWs 
Not reported Not reported Unadj. OR for higher vs. 
lower administrative 
score 0.94 (95% CI 0.87–
1.02), p = 0.12 
Adj. OR for higher vs. 
lower administrative 
score 0.97 (95% CI  
0.90–1.04), p = 0.36 
• Median administrative score 21 
(IQR 18–24, range 15–28); max 
possible score 32 
• Adj. OR adjusted for 
environmental score, PPE 
score, miscellaneous score, and 
number of TB patients 
Claassens, 
201325 
South 
Africa 
No Yes No Yes TB disease | 
HCWs 
Not reported Not reported Unadj. OR for higher vs. 
lower administrative 
score (continuous): 1.09 
(95% CI 0.99–1.19), p = 
0.07 
• Administrative score: range 
from −4 to 19, mean 8 (SD 4). 
Administrative score not 
included in adjusted model 
• ORs also shown for total, 
environmental controls, and 
personal respiratory protection 
scores   
da Costa, 200926 Brazil No Yes No Yes TST 
conversion 
rate | HCWs 
1998–2001: 
5.8 (95% CI 4.9–6.7) per 
1,000 PM (25 events in 
4,307 PM) 
2002–2003: 
3.7 (95% CI 2.8–4.6) per 
1,000 PM (15 events in 
3,858 PM) 
Hazard ratio = 0.46 (95% 
CI 0.23–0.89), p = 0.006 
• Adjusted hazard ratio 0.24 (95% 
CI 0.10–0.54), adjusted for 
exposure to person with PTB in 
hospital & occupation. 
• Fidelity: reduced time between 
microscopy request and result 
between two time-periods 
• Increased proportion of PTB 
diagnosed among suspected 
cases isolated 
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Roth, 200527 Brazil Yes Yes No Yes TST 
prevalence | 
HCWs  
TST prevalence:  
Hosp C: 65.8% 
(574/872); Hosp D: 
62.2% (454/730) 
TST prevalence:  
Hosp A: 46.7% 
(407/872);  
Hosp B: 69.6% 
(1,353/1,945) 
Hospital C & D, 
16.0/1,000 PM vs. A & B, 
7.8/1,000 PM; p <0.001. 
Hospitals B, C, and D vs. 
A: unadj. OR 1.3, 3.2, and 
3.4, respectively; adj. OR 
(95% CI; p-value) 1.0 
(0.5–1.8; NS), 2.3 (1.2–
4.2; 0.01), 2.8 (1.4–5.6; 
0.002), respectively. 
• Reported annual number of 
new PTB cases: Hosp A 200–
250; Hosp B 100–150; Hosp C 
450–500; and Hosp D 50–60 
TST 
conversion 
rate | HCWs 
TST conversion:  
Hosp C: 19.8/1,000 PM 
(n = 34);  
Hosp D: 12.2/1,000 PM 
(n = 21) 
TST conversion:  
Hosp A: 7.4/1,000 PM (n 
= 19);  
Hosp B: 8.1/1,000 PM (n 
= 31) 
Yanai, 200328 Thailand Yes Yes No Yes TST 
conversion 
rate | HCWs 
TST conversion 
1995–1997: 9.3 (95% CI 
3.3–15.3) per 100 PY 
TST conversion 
1998: 6.4 (95% CI 1.5–
11.4) per 100 PY;  
1999: 2.2 (95% CI 0–5.1) 
per 100 PY 
TST conversion  
Rate ratio (vs. 1995–
1997) 
1998: unadj. 0.9 (0.4–
2.2); adj. 0.4 (0.1–1.6), p 
= 0.2. 
1999: unadj. 0.03 (0.01–
0.2); adj. 0.01 (0–0.04), p 
<0.001 
• Intervention implemented in 
1996. Increase in numbers of 
smear-positive TB patients 
identified 1990 (102) to 1999 
(356) 
• Numerators & denominators 
unclear 
• Active TB disease incidence 
among HCWs also reported for 
the period 1988–1994 
TB disease 
rate | HCWs 
TB disease 
1995–1997: 0.65 
(29/4,464) per 100 PY 
 
TB disease 
1998: 0.42 (7/1,654) per 
100 PY; 
1999: 0.44 (7/1,583) per 
100 PY 
TB disease 
No rate ratio reported 
Harries, 200229 Malawi Yes Yes No Yes TB disease | 
HCWs 
1996: 3.7% (100/2,697) 1999: 3.2% (96/2,979) Reported as "non-
significant" 
• Fidelity (Jan–Jun 1998 vs. Jan–
Jun 1999): similar length of 
time from admission to 
diagnosis and treatment 
LOW BURDEN           
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Welbel, 200931 USA Yes Yes Yes Yes TST 
conversion 
rate | HCWs 
1994: 4.22/100 PY 
1995: 2.92/100 PY;  
1996: 1.41/100 PY;  
1997: 1.48/100 PY 
1998: 0.74/100 PY;  
1999: 0.57/100 PY;  
2000: 1.04/100 PY;  
2001: 0.71/100 PY;  
2002: 0.28/100 PY 
2002 vs. 1994: p <0.001 
1997 vs. 1994: p <0.001  
2002 vs. 1997: p = 0.14 
• Number of inpatients with 
active TB declining from 1997 
onwards 
Baussano, 
200732 
Italy Yes Yes No Yes TST 
conversion 
rate | HCWs 
Jan 1998–Jun 2000:  
2.19 (95% CI 1.81–2.56) 
per 100 PY  
(106 events in 4,034 PY) 
Jan 2002–Dec 2004:  
0.84 (95% CI 0.55–1.28) 
per 100 PY  
(42 events in 4,463 PY) 
Not reported. • Events per PY includes data to 
Dec 2001. 
• Data also shown by occupation 
(work activity) & workplace 
Jones, 200233 USA No Yes No Yes TST 
conversion | 
HCWs 
 Overall (1995–1998): 
2.3% (92/~4000);  
In SI/ID unit 
Jan 1994–Jan 1998: 0% 
(0/60);  
Feb–Jun 1998: 3.33% 
(2/60) 
Not reported • Fidelity: 50 patients placed on 
pathway from 1995–1998 
Moro, 200034 Italy Yes Yes No Yes MDR-TB 
incidence rate 
| HIV-positive 
in-patients 
Oct–Jun 1993: 
10.6/1,000 PD (26 events 
in 2,455 PD; 90 
individuals exposed) 
Jul 1993–Feb 1994: 
0/1,000 PD (0 events in 
654 PD; 44 individuals 
exposed) 
 Not reported. • 37 patients exposed in both 
before and after period: 
0/1,839 MDR-TB episodes 
• Over the entire time period 
there were several infectious 
MDR-TB cases in the ward 
Bangsberg, 
199935 
USA No Yes No Yes TST 
conversion 
rate | HCWs 
Jun 1992: 5.8/100 PY  
(9/88 [10.3%]) 
Dec 1992: 5.1/100 PY  
(2/77 [2.6%]);  
Jun 1993: 0/100 PY  
(0/88 [0%]);  
Dec 1993: 2.3/100 PY  
(1/93 [1.1%]);  
Jun 1994: 0/100 PY  
(0/86 [0%]) 
Not reported overall. 
Data also reported for 
interns showing a decline 
over 1992–1994 
(p = 0.029) 
• Fidelity: proportion properly 
isolated increased from 38% 
(Jan–Jun 1992) to 75% (Jul–Dec 
1993) 
• Participation of house staff 
ranged from 77% to 88% in the 
years reported. 
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Behrman, 199836 USA Yes Yes No Yes TST 
conversion | 
HCWs 
Jul 1994–Dec 1995 (cycle 
2)  
ED staff: 12.0% (6/50) 
Other hospital 
employees: 2.1% 
(51/2,514) 
1996 (cycle 3) 
ED staff: 0% (0/64) 
Other hospital 
employees: 1.2% 
(36/3,000) 
Not reported • No change in the number of 
culture-positive admissions 
from 1993–1996. No data 
reported on frequency of use of 
respiratory isolation rooms.  
• No data on TST conversions 
from Mar 1993–Dec 1994 (cycle 
1).  
Blumberg, 
199837 
USA Yes Yes No Yes TST 
conversion 
rate | HCWs 
Jul–Dec 1992:  
5.98/100 PY (21 
conversions) 
Jan 1993–Jun 1997:  
1.09/100 PY (31 
conversions) 
Not reported, but 
reported a p-value 
comparing the two time-
periods: <0.001 
• Also showed data separately 
for US medical school graduate 
staff during and after 
implementation (5.26 vs. 
0.72/100 PY, p <0.001; 17 and 
19 conversions, respectively) 
Louther, 199738 USA Yes Yes No Yes TST 
conversion | 
HCWs 
1991–1992  
Overall 7.2 conversions 
per 100 PY (65 events in 
898 PY) 
Lab workers 6.3 (3/48); 
Physicians/nurses 7.2 
(26/363); Social service 
8.1 (9/111); 
Housekeeping 11.7 
(21/179);  
Finance 3.0 (6/197) 
1993–1994 
Overall 3.3 conversions 
per 100 PY (32 events in 
971 PY) 
Lab workers 2.3 (1/44); 
Physicians/nurses 3.0 
(12/398); Social service 
2.2 (3/139); 
Housekeeping 6.7 
(12/179); Finance 1.9 
(4/211) 
Overall crude rate ratio 
0.46‡; p = 0.001 
Lab workers 0.37, p = 
0.42; Physicians/nurses 
0.42, p = 0.01; Social 
service 0.27, p = 0.04; 
Housekeeping 0.57, p = 
0.12; Finance 0.63, p = 
0.48 
 
• Number of new cases of TB per 
year ranged from 56 to 118 
over study period 
• Isolation days per year ranged 
from 6,360 to 10,883 over 
study period 
• Information on TST available 
for >90% of all employees 
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Uyamadu, 
199722 
USA No Yes No No TST 
conversion | 
HCWs 
1988–1990: overall 0.6% 
(23/3,842);  
Jan–Jul 1991: 1.7% 
(13/768).  
 
Jul 1991–Dec 1994: 
average 0.6% 
Jul–Dec 1991: 1.3% 
(10/774) 
1992: 0.5% (9/1,637) 
1993: 0.7% (9/1,325) 
1994: 0.6% (8/1,381) 
 
Not reported. • Fidelity: 100% compliance with 
respiratory isolation  
• Number of new TB cases in 
hospital remained stable from 
1991–1994 
Sinkowitz, 
199640 
USA No Yes No Yes TST 
conversion | 
Bronchoscopis
ts 
All 4 criteria - no: 
Bronchoscopists  
No TB pts: 0% (n = 16); 
1-5 TB pts: 8.0%;  (n = 
22);  
≥6 TB pts: 5.1% (n = 11) 
All 4 criteria - yes: 
Bronchoscopists  
No TB pts: 3.3% (n = 13); 
1-5 TB pts: 8.3% (n = 39); 
≥6 TB pts: 5.7% (n = 16) 
Not reported. • Results also reported for 
negative-pressure, air exhaust, 
& respiratory protection 
criterion 
TST 
conversion | 
HCWs 
HCWs 
No TB pts: 0.49% (n = 
127); 
1-5 TB pts: 0.64% (n = 
116);  
≥6 TB pts 0.76% (n = 34) 
HCWs 
No TB pts: 0.53% (n = 
75); 
1-5 TB pts: 0.69% (n = 
185);  
≥6 TB pts 0.90% (n = 66) 
Blumberg, 
199541 
USA Yes Yes No Yes TST 
conversion |  
HCWs 
Jan–Jun 1992: 3.3% 
(118/3,579) 
Jul–Dec 1992: 1.7% 
(51/2,975);  
Jan–Jun 1993: 1.4% 
(67/4,715);  
Jul–Dec 1993: 0.6% 
(30/4,775);  
Jan–Jun 1994: 0.4% 
(23/5,153) 
Not reported. 
Reported p-value 
comparing the five time-
periods: <0.001 
• Fidelity to the intervention: Jul 
1991–Feb 1992 (8 mths) 4.4 TB 
exposure episodes/mth 
(35/103 not appropriately 
isolated) vs. Mar 1992–Jun 
1994 (28 mths) 0.6 TB exposure 
episodes/mth (18/358 not 
appropriately isolated) 
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Fridkin, 199542 USA No Yes No Yes TST 
conversion | 
HCWs 
All 4 criteria - No: 1.89% 
(383/20,296; 17 
hospitals). 
≥3 criteria - No: 1.83% 
(380/20,776; 16 
hospitals). 
All 4 criteria - Yes: 0.60% 
(348/57,600; 28 
hospitals). 
≥3 criteria - Yes: 0.62% 
(376/60,371; 30 
hospitals). 
All 4 criteria: Yes vs. No: 
p = 0.02;  
≥3 criteria: Yes vs. No: p 
= 0.03 
• Similar trend for at least 
negative-pressure or at least 
the direct outside exhausted air 
criterion 
• Also restricted analysis to high 
risk HCWs (includes 
bronchoscopists & respiratory 
therapists) and found similar 
results 
Holzman, 199543 
§ 
USA Yes Yes No Yes TST 
conversion | 
HCWs 
Nov 1992–Oct 1993: 
Overall 90/2,132 (4.2%); 
Nursing 54/608 (8.9); 
Housekeeping 9/105 
(8.6); 
Radiology 2/50 (4.0); 
Misc./Unk. 14/474 (3.0) 
Nov 1993–Oct 1994 
Overall 23/1,995 (1.2%);  
Nursing 11/519 (2.1);  
Housekeeping 3/90 (3.3); 
Radiology 1/74 (1.4); 
Misc./Unk. 1/573 (0.2) 
Percentage reduction 
(95% CI), p-value 
Overall 73% (57–43), p 
<0.001; 
Nursing 76% (44–90), p 
<0.001; 
Housekeeping 61% (0–
89); 
Radiology 66% (0–97); 
Misc./Unk. 94% (55–99), 
p <0.001 
 
Jarvis, 199545 USA No Yes Yes Yes TST 
conversion | 
HCWs 
Baseline period (not 
defined): 
A: 24% (7/29);  
B: 9% (2/22);  
D:  12% (15/123) 
Intervention period (not 
defined) 
A: 0% (0/23);  
B: 18% (6/33);  
D: 3% (5/150) 
A: p = 0.01;  
B: p = NS;  
D: p = 0.01 
• Fidelity: proportion of patients 
on ward with same-ward 
exposures decreased in 
intervention (15%) vs. baseline 
period (74%). Decreased in all 
hospitals 
• In hospital B there was 
incomplete implementation of 
CDC guidelines 
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First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Maloney, 199546 USA No Yes Yes Yes TST 
conversion | 
HCWs 
Jan 1990–Jun 1991 
Overall: 3.1% (26/840) 
Wards housing TB 
patients: 16.7% (15/90);  
Other wards: 2.8% 
(7/254) 
Jul 1991–Aug 1992 
Overall: 3.0% (22/727) 
Wards housing TB 
patients: 5.1% (4/78);  
Other wards: 4.0% 
(9/228) 
Overall: p = 0.9 
Wards housing TB 
patients: relative risk = 
3.2, p = 0.02;  
Other wards: relative 
risk = 0.7, p = 0.5 
• TST conversion data also 
reported subgroup direct/no 
direct patient contact 
• Fidelity: AFB isolation before 
40% vs. after 90%; receiving 
adequate treatment before 
43% vs. after 90% 
Stroud, 199547 USA Yes Yes Yes Yes MDR-TB risk | 
AIDS patients 
Jan 1989–Mar 1990 
(period 1): 8.8% (19/216) 
Apr 1990–May 1991 
(period 2): 2.6% (5/193) 
p = 0.01 • Period 1, n = 16 patients with 
MDR-TB; Period 2, n = 22 
patients with MDR-TB 
• MDR-TB risk was 4.8% (4/84) 
for those with exposures to 
periods 1 and 2; and 0.5% 
(4/863) for AIDS patients 
without same-ward exposure 
Wenger, 199548 USA Yes Yes Yes Yes TST 
conversion | 
HCWs 
Jan–May 1990: 28% 
(7/25) 
Jun 1990–Feb 1991 
[early]: 18% (3/17);  
Mar 1991–Jun 1992 
[late]: 0% (0/23) 
Chi-square for trend (3 
time-periods), p <0.01 
• Stringent isolation criteria were 
only put into effect in Feb 1991  
Bryan, 198349 USA No Yes No Yes TST 
conversion | 
HCWs 
1976: 4.5% 1977: 5.1%;  
1979: 1.5%;  
1980: 0.85%;  
1981: 0.59% 
 • Possible problem of faulty 
performance of test/ presence 
of booster phenomenon in 
1976–1977 
• n/N not reported 
• Fidelity of intervention 
(proportion of patients with 
culture confirmed TB who were 
isolated): 1976: 3/15; 1977: 
9/24; 1978: 8/23; 1979: 18/30; 
1980: 14/26 
 
 Page 35 of 39 
First author, 
year published, 
[ref] 
Country Intervention/s Outcome/s | 
Population/s 
Primary findings Other findings 
Trig Isoln Tx Oth† No intervention Intervention Effect estimate 
Jacobson, 1957 
21 
USA Yes No No No TB disease 
incidence rate 
| HCWs 
1942–1951 (overall time 
period): 2.0/1,000 PY (78 
events in 38,331 PY); 
 
1952-1953: 1.0/1,000 PY 
(9 events in 9,030 PY);  
1954–1955: 0.3/1,000 PY 
(3 events in 9,199 PY) 
Not reported. • Peak in 1948–1950 coincided 
with community wide case-
finding activities 
• Also showed data by HCWs 
occupation 
*Based on WHO 2016 definitions15 491 
†Includes administrative, personal protective, and environmental IPC measures 492 
‡Rate ratios derived from data presented and not included in authors’ analysis 493 
§Conference abstract only 494 
adj.: adjusted; AFB: acid-fast bacilli; AIDS: acquired immune deficiency syndrome; CDC: Centers for Disease Control and Prevention; CI: confidence interval; HCWs: health care 495 
worker; Isoln: isolation or spatial separation; IPC: infection prevention and control; LTBI: latent TB infection; MDR: multidrug-resistant; misc.: miscellaneous; mth: month; OR: odds 496 
ratio; Oth: other; PD: person-days; PM: person-months; PPE: personal protective equipment; pt: patient; PY: person-years; ref: reference; SD: standard deviation; SI/ID: Special 497 
Immunology/Infectious Disease; TB: tuberculosis; Trig: triage of people with signs or symptoms of TB; TST: tuberculin skin test; Tx: effective treatment based on drug susceptibility; 498 
unadj.: unadjusted; unk.: unknown; USA: United States of America; Y: Yes  499 
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Table 5. Summary of quality assessments for retrospective studies* (n = 18 studies) 500 
First author Year Reporting 
(max = 11) 
External validity 
(max = 3) 
Internal validity: 
bias 
(max = 7) 
Internal validity: 
confounding 
(max = 6) 
Total, n (%/27) 
Bangsberg 1999 5 2 4 1 12 (44.4) 
Blumberg 1995 6 2 4 1 13 (48.2) 
Blumberg 1997 6 2 4 1 13 (48.2) 
Bryan 1983 3 1 1 1 6 (22.2) 
Claassens 2013 6 1 2 2 11 (40.7) 
Fridkin 1995 4 0 2 1 7 (25.9) 
Harries 2002 7 1 4 1 13 (48.1) 
Holzman 1995 4 2 2 2 10 (37.0) 
Jacobson 1957 4 0 3 2 9 (33.3) 
Jarvis 1995 6 1 4 2 13 (48.1) 
Jones 2002 3 1 2 2 8 (29.6) 
Louther 1997 3 2 2 2 9 (33.3) 
Maloney 1995 5 2 2 1 10 (37.0) 
O’Hara 2017 7 1 1 3 12 (44.4) 
Sinkowitz 1996 6 0 4 2 12 (44.4) 
Stroud 1995 4 0 2 1 7 (25.9) 
Uyamadu 1997 3 0 2 1 6 (22.2) 
Welbel 2009 5 0 3 1 9 (33.3) 
*Assessed using the Downs & Black tool16 501 
  502 
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Table 6. Summary of quality assessment for prospective studies* (n = 7 studies) 503 
First author Year Sequence 
generation 
Allocation 
concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
of bias 
Baussano 2007 No No No Yes No No 
Behrman 1998 No No No No No No 
da Costa 2009 No No No No No No 
Moro 2000 No No No No Yes No 
Roth 2005 No No No No Yes No 
Wenger 1995 No No No No No No 
Yanai 2003 No No No No Yes No 
* Assessed using the Cochrane collaboration tool for experimental studies and prospective cohort studies 504 
(http://www.cochrane-handbook.org) 505 
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Figure 1. PRISMA flow diagram showing databases searched; numbers of records identified, sifted, reviewed, and included; and reasons for exclusion 506 
 507 
*References and citations were checked for 25 primary research articles, 19 systematic reviews, and six guidelines (see Supplementary table 3) 508 
PRISMA: preferred reporting items for systematic reviews and meta-analyses; Refs: references; SR: systematic review; WoS: Web of Science509 
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Figure 2. Venn diagrams showing overlap between interventions implemented in the 25 studies included 510 
 511 
Panel A: overlap between the three interventions of interest; Panel B: overlap between the three interventions of 512 
interest and other IPC measures implemented 513 
*Includes administrative, personal protective, and environmental IPC measures 514 
IPC: infection prevention and control 515 
Figure developed using Venny v2.1,23 Inkscape (https://inkscape.org/), and GIMP (https://www.gimp.org/) software. 516 
 517 
